Seroatlas · Human Serome Atlas

SIGLEC14

Sialic acid-binding Ig-like lectin 14

Also known as: SIG14_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q08ET2
Gene: SIGLEC14
Ensembl: ENSG00000254415
Chromosome: 19
Canonical length: 396 aa
Protein class: Plasma proteins, Predicted membrane proteins
Subcellular location: Vesicles,Plasma membrane

OverviewNCBI Gene

Predicted to enable sialic acid binding activity. Predicted to be involved in cell adhesion. Predicted to be located in ficolin-1-rich granule membrane and tertiary granule membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

396 residues, UniProt reviewed canonical sequence.

>Q08ET2|SIGLEC14
     1  MLPLLLLPLL WGGSLQEKPV YELQVQKSVT VQEGLCVLVP CSFSYPWRSW YSSPPLYVYW
    61  FRDGEIPYYA EVVATNNPDR RVKPETQGRF RLLGDVQKKN CSLSIGDARM EDTGSYFFRV
   121  ERGRDVKYSY QQNKLNLEVT ALIEKPDIHF LEPLESGRPT RLSCSLPGSC EAGPPLTFSW
   181  TGNALSPLDP ETTRSSELTL TPRPEDHGTN LTCQVKRQGA QVTTERTVQL NVSYAPQNLA
   241  ISIFFRNGTG TALRILSNGM SVPIQEGQSL FLACTVDSNP PASLSWFREG KALNPSQTSM
   301  SGTLELPNIG AREGGEFTCR VQHPLGSQHL SFILSVQRSS SSCICVTEKQ QGSWPLVLTL
   361  IRGALMGAGF LLTYGLTWIY YTRCGGPQQS RAERPG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SIGLEC14 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 22 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 22 nTPM
spleen: 21 nTPM
appendix: 12 nTPM
tonsil: 9.1 nTPM
lymph node: 8.1 nTPM
small intestine: 4.4 nTPM

Single-cell type

neutrophils: 8.9 nCPM
kupffer cells: 4.1 nCPM
monocytes: 1.8 nCPM
macrophages: 1.2 nCPM
cdc: 1.1 nCPM
monocyte progenitors: 1 nCPM

Immune cell

neutrophil: 80 nTPM
intermediate monocyte: 71 nTPM
non-classical monocyte: 59 nTPM
classical monocyte: 58 nTPM
myeloid DC: 35 nTPM
total PBMC: 20 nTPM

Brain region

medulla oblongata: 12 nTPM
thalamus: 10 nTPM
pons: 9.8 nTPM
white matter: 9.5 nTPM
hypothalamus: 9.2 nTPM
cerebral cortex: 8.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.89
gnomAD pLI: 0
gnomAD missense Z: 0.44

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

cell adhesion

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SIGLEC14 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

TYROBP

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SIGLEC14 as an antibody target. Whether an autoantibody or antibody against SIGLEC14 could matter depends on whether native SIGLEC14 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SIGLEC14 is annotated at the cell surface, where native SIGLEC14 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SIGLEC14 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...